Ovarian cancer metastasis: Integrating insights from disparate model organisms

Nature Reviews Cancer

Volumn 5, Issue 5, 2005, Pages 355-366

  Naora, Honami ^a   Montell, Denise J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CASPASE INHIBITOR; CCAAT ENHANCER BINDING PROTEIN; COFILIN; CYTOKINE; DNA BINDING PROTEIN; ECDYSONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; FILAMIN; JANUS KINASE; MYOSIN; MYOSIN II; PROFILIN; PROTEIN ADIPOCYTE ENHANCER BINDING PROTEIN 2; PROTEIN DIAP1; PROTEIN DOME; PROTEIN MAL D; PROTEIN MYOSIN VI; PROTEIN PAR 3; PROTEIN PAR 6; PROTEIN PVR; PROTEIN SRF; PROTEIN TYROSINE KINASE; PROTEIN UPD; RAC PROTEIN; RETINOID X RECEPTOR; STAT PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ANIMAL MODEL; ASCITES; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL DEATH; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; DROSOPHILA MELANOGASTER; GENETIC ANALYSIS; GENETIC SCREENING; HORMONE RESPONSE; METASTASIS; NONHUMAN; OOCYTE; OVARY CANCER; PATHOPHYSIOLOGY; PERITONEAL CAVITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ASCITES; CADHERINS; CELL ADHESION; CELL MOVEMENT; DROSOPHILA MELANOGASTER; FEMALE; GROWTH SUBSTANCES; MODELS, ANIMAL; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; OVARY; SIGNAL TRANSDUCTION;

EID: 18344380440     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1611     Document Type: Review

References (116)

1. Norbury, C. & Nurse, P. Controls of cell proliferation in yeast and animals. Ciba Found. Symp. 150, 168-177 (1990).
2. Metzstein, M. M., Stanfield, G. M. & Horvitz, H. R. Genetics of programmed cell death in C. elegans: past, present and future. Trends Genet. 14, 410-416 (1998).
3. Edwards, P. A. The impact of developmental biology on cancer research: an overview. Cancer Metastasis Rev. 18, 175-180 (1999).
4. Nusslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
5. Logan, C. Y. & Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004).
6. Peifer, M. & Wieschaus, E. The segment polarity gene armadillo encodes a functionally modular protein that is the Drosophila homolog of human plakogiobin. Cell 63, 1167-1176 (1990).
7. Gumbiner, B. M. Signal transduction of β-catenin. Curr. Opin. Cell Biol. 7, 634-640 (1995).
8. Nelson, W. J. & Nusse, R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
9. Montell, D. J. Command and control: regulatory pathways controlling invasive behavior of the border cells. Mech. Dev. 105, 19-25 (2001).
10. Rorth, P. Initiating and guiding migration: lessons from border cells. Trends Cell Biol. 12, 325-331 (2002).
11. Montell, D. J. Border-cell migration: the race is on. Nature Rev. Mol. Cell Biol. 4, 13-24 (2003).
12. Jemal, A. et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
13. Pfistersr, J., Hilpert, F., Du Bois, A., Meier, W. & Wagner, U. State-of-the-art first-line treatment of ovarian cancer. Onkologie 26, 446-450 (2003).
14. Eltabbakh, G. H. Recent advances in the management of women with ovarian cancer. Minerva Ginecol. 56, 81-89 (2004).
15. Sonoda, Y. Management of early ovarian cancer. Oncology 18, 343-56 (2004).
16. Feeley, K. M. Swells, M. Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87-95 (2001).
17. Dubeau, L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol. Oncol. 72, 437-442 (1999).
18. Orsulic, S. et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1, 53-62 (2002).
19. Connolly, D. C. et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63, 1389-1397 (2003).
20. Flesken-Nikitin, A., Choi, K. C., Eng, J. P., Shmidt, E. N. & Nikitin, A. Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63, 3459-3463 (2003).
21. Dinulescu, D. M. et al. Role of K-ras and Ren in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Med. 11, 63-70 (2005).
22. Shih I, M. & Kurman, R. J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164, 1511-1518 (2004). References 16,17 and 22 present contrasting views of the origin and histogenesis of epithelial ovarian tumours.
23. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002).
24. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004). References 23 and 24 provide comprehensive overviews of haematogenous and lymphatic dissemination of cancer cells.
25. Tsuruchi, N. et al. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer: a multivariate analysis. Gynecol. Oncol. 49, 51-55 (1993).
26. Morice, P. et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J. Am. Coll. Surg. 197, 198-205 (2003).
27. Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255-288 (2001). An insightful and comprehensive overview of ovarian surface epithelial cell biology.
28. Burleson, K. M. et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93, 170-181 (2004).
29. Mutsaers, S. E. Mesothelial cells: their structure, function and role in serosal repair. Respirology 7, 171-191 (2002).
30. Bai, J., Uehara, Y. & Montell, D. J. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell 103, 1047-1058 (2000).
31. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997).
32. Torres-Arzayus, M. I. et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274 (2004).
33. Tanner, M. M. et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. 6, 1833-1839 (2000).
34. Hayashido, Y. et al. Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int. J. Cancer 75, 654-658 (1998).
35. Kuang, S. Q. et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 64, 1875-1885 (2004).
36. Oh, A. et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 64, 8299-8308 (2004).
37. Duchek, P., Somogyi, K., Jekely, G., Beccari, S. & Rorth, P. Guidance of cell migration by the Drosophila PDGF/VEGF receptor. Cell 107, 17-26 (2001). Shows that the EGF receptor and PVF1 receptor function redundantly in border-cell migration.
38. McDonald, J. A., Pinheiro, E. M. & Monteli, D. J. PVF1, a PDGF/VEGF homolog, is sufficient to guide border cells and interacts genetically with Taiman. Development 130, 3469-3478 (2003). Shows that PVF1 is a guidance factor by demonstrating that ectopic expression of PVF1 can direct border cells to migrate to a new location.
39. Bartlett, J. M. et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 73, 301-306 (1996).
40. Chen, Z. et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1α and epidermal growth factor. Cancer 92, 3068-3075 (2001).
41. Alper, O. et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Natl Cancer Inst. 93, 1375-1384 (2001).
42. Ellerbroek, S. M. et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61, 1855-1861 (2001).
43. Zebrowski, B. K. et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6, 373-378 (1999).
44. Nagy, J. A. et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 55, 360-368 (1995).
45. Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721-5728 (2003). Shows that VEGF is a causative factor in ascites accumulation.
46. Mesiano, S., Ferrara, N. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153, 1249-1256 (1998).
47. Xu, L. et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. 16, 445-454 (2000).
48. Chen, H., Ye, D., Xie, X., Chen, B. & Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol. 94, 630-635 (2004).
49. Bartoli, M. et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 275, 33189-33192 (2000).
50. Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931-4941 (2004).
51. Pustilnik, T. B. et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5, 3704-3710 (1999).
52. Fishman, D. A., Liu, Y., Ellerbroek, S. M. & Stack, M. S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61, 3194-3199 (2001).
53. Bian, D. et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK Kinase 1 pathway. Cancer Res. 64, 4209-4217 (2004).
54. Ren, X. D. et al. Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. J. Cell Sci. 113, 3673-3678 (2000).
55. Santos, A. C. & Lehmann, R. Germ cell specification and migration in Drosophila and beyond. Curr. Biol. 14, R578-R589 (2004).
56. Niewiadomska, P., Godt, D. & Tepass, U. DE-Cadherin is required for intercellular motility during Drosophila oogenesis. J. Cell Biol. 144, 533-547 (1999).
57. Sundfeldt, K. et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer 74, 275-280 (1997).
58. Sundfeldt, K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol. Cell Endocrinol. 202, 89-96 (2003).
59. Marques, F. R., Fonsechi-Carvasan, G. A., De Angelo Andrade, L. A. & Bottcher-Luiz, F. Immunohistochemical patterns for α- and β-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol. Oncol. 94, 16-24 (2004).
60. Kang, Y. & Massague, J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279 (2004).
61. Rangel, L. B. et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin. Cancer Res. 9, 2567-2575 (2003).
62. Abdelilah-Seyfried, S., Cox, D. N. & Jan, Y. N. Bazooka is a permissive factor for the invasive behavior of discs large tumor cells in Drosophila ovarian follicular epithelia. Development 130, 1927-1935 (2003).
63. Pinheiro, E. M. & Montell, D. J. Requirement for Par-6 and Bazooka in Drosophila border cell migration. Development 131, 5243-5251 (2004).
64. Cheng, W., Liu, J., Yoshida, H., Rosen, D. & Naora, H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nature Med. 10 Apr 2005 (doi:10.1038/nm1230).
65. Geisbrecht, E. R. & Montell, D. J. Myosin VI is required for E-cadherin-mediated border cell migration. Nature Cell Biol. 4, 616-620 (2002). Shows the requirement for D. metanogaster myosin VI in border-cell migration.
66. Yoshida, H. et al. Lessons from border cell migration in the Drosophila ovary: a role for myosin VI in dissemination of human ovarian cancer. Proc. Natl Acad. Sci. USA 101, 8144-8149 (2004). Shows that myosin VI contributes to the motility of ovarian carcinoma cells in vitro and in the mouse.
67. Buss, F., Luzio, J. P. & Kendrick-Jones, J. Myosin VI, an actin motor for membrane traffic and cell migration. Traffic 3, 851-858 (2002).
68. Schober, M. & Perrimon, N. Unconventional ways to travel. Nature Cell Biol. 4, E211-E212 (2002).
69. Silver, D. L. & Montell, D. J. Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in Drosophila. Cell 107, 831-841 (2001).
70. Beccari, S., Teixeira, L. & Rorth, P. The JAK/STAT pathway is required for border cell migration during Drosophila oogenesis. Mech. Dev. 111, 115-123 (2002).
71. Xi, R., McGregor, J. R. & Harrison, D. A. A gradient of JAK pathway activity patterns the anterior-posterior axis of the follicular epithelium. Dev. Cell 4, 167-177 (2003).
72. Huang, M., Page, C., Reynolds, R. K. & Lin, J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol. Oncol. 79, 67-73 (2000).
73. Silver, D. L., Naora, H., Liu, J., Cheng, W. & Montell, D. J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 64, 3550-3558 (2004).
74. Geisbrecht, E. R. & Montell, D. J. A role for Drosophila IAP1-mediated caspase inhibition in Rac-dependent cell migration. Cell 118, 111-125 (2004). Shows that the DIAP1 protein is required for motility rather than for cell survival in border cells.
75. Sasaki, H., Sheng, Y., Kotsuji, F. & Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60, 5659-5666 (2000).
76. Fraser, M. et al. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol. 1, 66 (2003).
77. Hibbs, K. et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165, 397-414 (2004).
78. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
79. Bernards, R. & Weinberg, R. A. A progression puzzle. Nature 418, 823 (2002).
80. Woelfle, U. et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 63, 5679-5684 (2003).
81. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). Reports that chemokines and their receptors determine the metastatic destination of tumour cells.
82. Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G. & Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961-4965 (2001).
83. Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72-77 (1998).
84. Scotton, C. J. et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-5938 (2002).
85. Foussat, A. et al. Production of stromal cell-derived factor 1 by mesothelial cells and effects of this chemokine on peritoneal B lymphocytes. Eur. J. Immunol. 31, 350-359 (2001)
86. Freedman, R. S., Deavers, M., Liu, J. & Wang, E. Peritoneal inflammation: a micro-environment for epithelial ovarian cancer (EOC). J. Transl. Med. 2, 23 (2004).
87. Gardner, M. J., Catterall, J. B., Jones, L. M. & Turner, G. A. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin. Exp. Metastasis 14, 325-334 (1996).
88. Strobel, T., Swanson, L. & Cannistra, S. A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 57, 1228-1232 (1997).
89. Bourguignon, L. Y., Gilad, E., Rothman, K. & Peyollier, K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling leading to actin binding, Elk-1/estrogen receptor transcriptional activation and ovarian cancer progression. J. Biol. Chem. 280, 11961-11972 (2005).
90. Rump, A. et al. Binding of ovarian cancer antigen CA125/ MUC16 to mesothelin mediates cell adhesion. J Biol. Chem. 279, 9190-9198 (2004).
91. Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R, B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087-1092 (2002).
92. Hu, L. et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161, 1917-1924 (2002).
93. Sun, J. et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 59, 4919-4926 (1999).
94. Adjei, A. A. et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 9, 2520-2526 (2003).
95. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
96. Xie, K. & Abbruzzese, J. L. Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell 4, 245-247 (2003).
97. Pietsch, T., Taylor, M. D. & Rutka, J. T. Molecular pathogenesis of childhood brain tumors. J. Neurooncol. 70, 203-215 (2004).
98. Sheng, T. et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 3, 29 (2004).
99. Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 707-712 (2004).
100. Sanchez, P. et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl Acad. Sci. USA 101, 12561-12566 (2004).
101. Pagliarini, R. A. & Xu, T. A genetic screen in Drosophila for metastatic behavior. Science 302, 1227-1231 (2003).
102. Jackson, G. R. et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21, 633-642 (1998).
103. Reifer, M. & Yap, A. S. Traffic control: p120-catenin acts as a gatekeeper to control the fate of classical cadherins in mammalian cells. J. Cell Biol. 163, 437-440 (2003).
104. Davies, B. R., Worsley, S. D. & Ponder, B. A. Expression of E-cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32, 69-80 (1998).
105. Montell, D. J., Rorth, P. & Spradling, A. C. slow border cells, a locus required for a developmentally regulated cell migration during oogenesis, encodes Drosophila C/EBP. Cell 71, 51-62 (1992).
106. Rorth, P. & Montell, D. J. Drosophila C/EBP: a tissue-specific DNA-binding protein required for embryonic development. Genes Dev. 6, 2299-2311 (1992).
107. Rorth, P., Szabo, K. & Texido, G. The level of C/EBP protein is critical for cell migration during Drosophila oogenesis and is tightly controlled by regulated degradation. Mol. Cell 6, 23-30 (2000).
108. Verheyen, E. M. & Cooley, L. Profilin mutations disrupt multiple actin-dependent processes during Drosophila development. Development 120, 717-728 (1994).
109. Murphy, A. M. & Montell, D. J. Cell type-specific roles for Cdc42, Rac, and RhoL in Drosophila oogenesis. J. Cell Biol. 133, 617-630 (1996).
110. Oda, H., Uemura, T. & Takeichi, M. Phenotypic analysis of null mutants for DE-cadherin and Armadillo in Drosophila ovaries reveals distinct aspects of their functions in cell adhesion and cytoskeletal organization. Genes Cells 2, 29-40 (1997).
111. Edwards, K. A. & Kiehart, D. P. Drosophila nonmuscle myosin II has multiple essential roles in imaginal disc and egg chamber morphogenesis. Development 122, 1499-1511 (1996).
112. Liu, Y. & Montell, D. J. Jing: a downstream target of slbo required for developmental control of border cell migration. Development 128, 321-330 (2001).
113. Duchek, P. & Rorth, P. Guidance of cell migration by EGF receptor signaling during Drosophila oogenesis. Science 291, 131-133 (2001).
114. Chen, J. et al. Cofilin/ADF is required for cell motility during Drosophila ovary development and oogenesis. Nature Cell Biol. 3, 204-209 (2001).
115. Sokol, N. S. & Cooley, L. Drosophila filamin is required for follicle cell motility during oogenesis. Dev. Biol. 260, 260-272 (2003).
116. Somogyi, K. & Rorth, P. Evidence for tension-based regulation of Drosophila MAL and SRF during invasive cell migration. Dev. Cell 7, 85-93 (2004).